Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Profit After Tax (2016 - 2025)

Avalo Therapeutics filings provide 12 years of Profit After Tax readings, the most recent being -$13.8 million for Q4 2025.

  • On a quarterly basis, Profit After Tax rose 60.95% to -$13.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$78.3 million, a 123.0% decrease, with the full-year FY2025 number at -$78.3 million, down 122.89% from a year prior.
  • Profit After Tax hit -$13.8 million in Q4 2025 for Avalo Therapeutics, up from -$30.6 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $98.5 million in Q2 2024 to a low of -$121.3 million in Q1 2024.
  • Median Profit After Tax over the past 5 years was -$13.5 million (2025), compared with a mean of -$13.6 million.
  • The widest YoY moves for Profit After Tax: up 1301.79% in 2024, down 1118.38% in 2024.
  • Avalo Therapeutics' Profit After Tax stood at -$19.1 million in 2021, then skyrocketed by 48.71% to -$9.8 million in 2022, then rose by 16.75% to -$8.2 million in 2023, then crashed by 332.65% to -$35.3 million in 2024, then surged by 60.95% to -$13.8 million in 2025.
  • The last three reported values for Profit After Tax were -$13.8 million (Q4 2025), -$30.6 million (Q3 2025), and -$20.8 million (Q2 2025) per Business Quant data.